BioWorld - Thursday, July 9, 2026

Drug design, drug delivery and technologies
Drug design, drug delivery and technologies RSS Feed RSS

Test tubes, dropper and capsules
Drug Design, Drug Delivery & Technologies

Proteros and Orion establish multitarget collaboration

Sep. 8, 2023
Proteros Biostructures GmbH has established a new collaboration with Orion Corp. The two companies are engaging in a joint multitarget collaboration for early-stage drug discovery projects in oncology and pain using Proteros’ discovery platform, and now have decided to combine their expertise to assemble a chemically diverse small-molecule library collection. The nonexclusive agreement enables Proteros to exclusively offer access to this high throughput screening (HTS) library to all its clients.
Read More
Infection

Acuitas tackles mRNA drug delivery challenges with lipid nanoparticles

Sep. 5, 2023
By Caroline Richards
Messenger RNA, or mRNA, represents a relatively new class of therapeutics with the potential to prevent and treat a wide range of diseases. A well-known success story is of the mRNA vaccines that controlled the COVID-19 pandemic, which has fueled enthusiasm for the field. But biotechs are also developing mRNA candidates for several other infectious diseases, including malaria, tuberculosis and HIV, as well for cancer, autoimmune and allergic diseases. However, delivering nucleic acid therapeutics can be challenging, since mRNA cannot get into cells on its own.
Read More
Drug Design, Drug Delivery & Technologies

Faster than light drug discovery: Superluminal launches with $33M seed round

Sep. 4, 2023
By Jennifer Boggs
As its name suggests, Superluminal Medicines Inc. is aiming for speed. The startup, which closed a $33 million seed round led by RA Capital Management, is combining a biology-focused approach with a generative AI platform it says has the potential to create candidate-ready compounds in a matter of months, with its initial sights set on G protein-coupled receptor targets.
Read More
Hands holding gears
Drug Design, Drug Delivery & Technologies

Serengen and Deargen establish drug discovery collaboration

Aug. 30, 2023
Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s artificial intelligence (AI)-driven drug discovery platform, Deardti.
Read More
Cancer research illustration

Multiple KRAS targeting strategies paving way for combination therapies

Aug. 29, 2023
By Mar de Miguel
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
Read More
Cancer research illustration
Cancer

Multiple KRAS targeting strategies paving way for combination therapies

Aug. 25, 2023
By Mar de Miguel
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
Read More